Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of the National Cancer Institute

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/dji027PMID 15657346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

  2005cited by this paper
• Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer.

  2004cited by this paper
• Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays

  2003cited by this paper
• Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)

  1998cited by this paper

• Predicting resistance to chemotherapy using chromosomal instability signatures

  2025cites this paper
• Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

  2025cites this paper
• Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer

  2024cites this paper
• CD47—a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features

  2024influential citation
• A signature of circulating miRNAs predicts the prognosis and therapeutic outcome of taxane/platinum regimen in advanced ovarian carcinoma patients

  2024influential citation
• Development of an Automatic Rule-Based Algorithm for the Detection of Ovarian Cancer Recurrence From Electronic Health Records

  2024cites this paper
• Radiomics Analysis for Clinical Decision Support in 177Lu-DOTATATE Therapy of Metastatic Neuroendocrine Tumors using CT Images

  2024cites this paper
• Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy with Bevacizumab as the Frontline Adjuvant Therapy in Advanced Ovarian Cancer

  2024cites this paper
• CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

  2023cites this paper
• Prognostic value of CA125 kinetics, half-life, and nadir in the treatment of epithelial ovarian cancer: a systematic review and meta-analysis

  2023cites this paper
• INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

  2023cites this paper
• Evaluation of numerical rating scale and neuropathic pain symptom inventory pain scores in advanced ovarian carcinoma patients undergoing surgery and first-line chemotherapy

  2022cites this paper
• Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.

  2021cites this paper
• The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review

  2021cites this paper
• Early prediction of neoadjuvant chemotherapy response by exploiting a transfer learning approach on breast DCE-MRIs

  2021cites this paper
• Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer

  2020cites this paper
• Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

  2020cites this paper
• Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study

  2020cites this paper
• Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m2 versus 40 mg/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial

  2020cites this paper
• First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.

  2020cites this paper
• Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer

  2020cites this paper
• Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil

  2019cites this paper
• Plasma MicroRNA-200c as A Prognostic Biomarker for Epithelial Ovarian Cancer

  2019cites this paper
• Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis

  2019cites this paper
• A radiologic-laparoscopic model to predict suboptimal (or complete and optimal) debulking surgery in advanced ovarian cancer: a pilot study

  2019cites this paper
• A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy

  2019cites this paper
• Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

  2019cites this paper
• Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer

  2019cites this paper
• Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer

  2019cites this paper
• Predictive model for major complications after extensive abdominal surgery in primary advanced ovarian cancer

  2019cites this paper
• Survival of advanced epithelial ovarian/fallopian tube/primary peritoneum carcinoma after high-complexity upper abdominal surgery

  2019cites this paper
• Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

  2019cites this paper
• Dynamic contrast enhanced‑magnetic resonance imaging for the early evaluation of the response to docetaxel in rats with epithelial ovarian cancer.

  2019cites this paper
• Syddansk Universitet Delta tocotrienol in recurrent ovarian cancer . A phase II trial

  2019cites this paper
• Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes

  2019cites this paper
• ePAD: An Image Annotation and Analysis Platform for Quantitative Imaging

  2019cites this paper
• Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancer.

  2019cites this paper
• In-hospital Mortality after Surgical Resection in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus

  2019cites this paper
• The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution

  2019cites this paper
• CMAR_A_198429 3583..3591

  2019cites this paper
• Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

  2019cites this paper
• Measurable Krukenberg tumor is preferably characterized as a non-target lesion in the clinical evaluation of gastric cancer therapeutics: A case report

  2018cites this paper
• Diffusion-weighted imaging and diffusion kurtosis imaging for early evaluation of the response to docetaxel in rat epithelial ovarian cancer

  2018cites this paper
• A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

  2018cites this paper
• Prognostic value of serum IL-8 and IL-10 in patients with ovarian cancer undergoing chemotherapy

  2018cites this paper
• Méthodes statistiques pour les essais de phase I/II de thérapies moléculaires ciblées en cancérologie

  2018cites this paper
• Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

  2018cites this paper
• Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis

  2018cites this paper
• A comparison between primary debulking surgery and primary chemotherapy in patients with advanced ovarian cancer: a retrospective study

  2018cites this paper
• The efficacy and safety of apatinib in Ewing’s sarcoma: a retrospective analysis in one institution

  2018cites this paper
• Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

  2017cites this paper
• Concurrent preoperative chemotherapy and three-dimensional conformal radiotherapy followed by surgery for oral squamous cell carcinoma: a retrospective analysis of 104 cases

  2017cites this paper
• The Research of Reproducibility and Non-redundancy Feature Selection Methods in Radiomics

  2017cites this paper
• Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells

  2017influential citation
• Efficacy and safety of dose-dense chemotherapy in urothelial carcinoma

  2017cites this paper
• Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors

  2017cites this paper
• Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.

  2017cites this paper
• Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer

  2017cites this paper
• Abbreviated Title:

  2017cites this paper
• The efficacy and safety of pegylated liposomal doxorubicin monotherapy and combination therapy with carboplatin in Korean patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer: a single-institution experience

  2017cites this paper
• Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer

  2017cites this paper
• Nintedanib in ovarian cancer

  2017cites this paper
• Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner

  2017cites this paper
• Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study

  2017cites this paper
• Carboplatin And Cyclosporin A In The Treatment Of Recurrent Epithelial Ovarian Cancer

  2016cites this paper
• The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer

  2016cites this paper
• Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer

  2016cites this paper
• Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study.

  2016cites this paper
• Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

  2016cites this paper
• Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer

  2016cites this paper
• University of Southern Denmark Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer

  2016cites this paper
• SSRI use and clinical outcomes in epithelial ovarian cancer

  2016cites this paper
• Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer

  2016cites this paper
• Syddansk Universitet Identification of high-risk patients by human epididymis protein 4 levels during follow- up of ovarian cancer

  2016cites this paper
• Exosomes for the Early Detection of Ovarian Cancer

  2016cites this paper
• Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

  2016cites this paper
• Oral cyclophosphamide in recurrent ovarian cancer

  2016cites this paper
• C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis

  2016cites this paper
• Effects of sequential paclitaxel–carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer

  2016cites this paper
• Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer

  2016cites this paper
• BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism

  2015cites this paper
• Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

  2015cites this paper
• Discover, Develop & Validate--Advance and Prospect of Tumor Biomarkers.

  2015cites this paper
• The new FIGO staging system and the review of current methods of detection of ovarian cancer

  2015cites this paper
• Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.

  2015cites this paper
• Bevacizumab in ovarian and cervical cancer a retrospective case series at Tampere University Hospital

  2015cites this paper
• Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies

  2015influential citation
• Immunomodulatory therapy in refractory/recurrent ovarian cancer.

  2015cites this paper
• Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer

  2015cites this paper
• Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer

  2015cites this paper
• Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy

  2015cites this paper
• The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score

  2015cites this paper
• Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

  2015cites this paper
• Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

  2015cites this paper
• Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer.

  2015cites this paper
• A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.

  2015cites this paper
• Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation.

  2015cites this paper
• Systematic Review of Monitoring Criteria to Interpret CA125 Increments during First-Line Chemotherapy and the Subsequent Follow-Up Period among Patients with Advanced Epithelial Ovarian Cancer

  2015cites this paper
• A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

  2014influential citation
• Statin Therapy Is Associated with Improved Survival in Patients with Non-Serous-Papillary Epithelial Ovarian Cancer: A Retrospective Cohort Analysis

  2014cites this paper